» Articles » PMID: 24272362

The Role of Complement in Tumor Growth

Overview
Date 2013 Nov 26
PMID 24272362
Citations 108
Authors
Affiliations
Soon will be listed here.
Abstract

Complement is a central part of the immune system that has developed as a first defense against non-self cells. Neoplastic transformation is accompanied by an increased capacity of the malignant cells to activate complement. In fact, clinical data demonstrate complement activation in cancer patients. On the basis of the use of protective mechanisms by malignant cells, complement activation has traditionally been considered part of the body's immunosurveillance against cancer. Inhibitory mechanisms of complement activation allow cancer cells to escape from complement-mediated elimination and hamper the clinical efficacy of monoclonal antibody-based cancer immunotherapies. To overcome this limitation, many strategies have been developed with the goal of improving complement-mediated effector mechanisms. However, significant work in recent years has identified new and surprising roles for complement activation within the tumor microenvironment. Recent reports suggest that complement elements can promote tumor growth in the context of chronic inflammation. This chapter reviews the data describing the role of complement activation in cancer immunity, which offers insights that may aid the development of more effective therapeutic approaches to control cancer.

Citing Articles

Proteogenomic Profiling of Treatment-Naïve Metastatic Malignant Melanoma.

Kuras M, Betancourt L, Hong R, Szadai L, Rodriguez J, Horvatovich P Cancers (Basel). 2025; 17(5).

PMID: 40075679 PMC: 11899103. DOI: 10.3390/cancers17050832.


Spatially distinct cellular and molecular landscapes define prognosis in triple negative breast cancer.

Mukund K, Veraksa D, Frankhouser D, Yang L, Tomsic J, Pillai R bioRxiv. 2025; .

PMID: 39990419 PMC: 11844391. DOI: 10.1101/2025.02.10.637503.


The role of the C5a-C5aR pathway in iron metabolism and gastric cancer progression.

Ni Q, Yang H, Rao H, Zhang L, Xiong M, Han X Front Immunol. 2025; 15():1522181.

PMID: 39850877 PMC: 11754390. DOI: 10.3389/fimmu.2024.1522181.


Three-dimensional genome architecture in intrahepatic cholangiocarcinoma.

Liang Y, Li C, Zou R, Ying L, Chen X, Wang Z Cell Oncol (Dordr). 2025; .

PMID: 39831920 DOI: 10.1007/s13402-024-01033-6.


Complement C3d enables cell-mediated immunity capable of distinguishing spontaneously transformed from nontransformed cells.

Platt J, Zhao C, Chicca J, Pianko M, Han J, The S Proc Natl Acad Sci U S A. 2024; 121(52):e2405824121.

PMID: 39693340 PMC: 11670236. DOI: 10.1073/pnas.2405824121.


References
1.
Klickstein L, Barbashov S, Liu T, Jack R, Nicholson-Weller A . Complement receptor type 1 (CR1, CD35) is a receptor for C1q. Immunity. 1997; 7(3):345-55. DOI: 10.1016/s1074-7613(00)80356-8. View

2.
Kolev M, Towner L, Donev R . Complement in cancer and cancer immunotherapy. Arch Immunol Ther Exp (Warsz). 2011; 59(6):407-19. DOI: 10.1007/s00005-011-0146-x. View

3.
Costello L, Franklin R . 'Why do tumour cells glycolyse?': from glycolysis through citrate to lipogenesis. Mol Cell Biochem. 2006; 280(1-2):1-8. PMC: 4461431. DOI: 10.1007/s11010-005-8841-8. View

4.
Schraufstatter I, Trieu K, Sikora L, Sriramarao P, DiScipio R . Complement c3a and c5a induce different signal transduction cascades in endothelial cells. J Immunol. 2002; 169(4):2102-10. DOI: 10.4049/jimmunol.169.4.2102. View

5.
Xu C, Jung M, Burkhardt M, Stephan C, Schnorr D, Loening S . Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy. Prostate. 2004; 62(3):224-32. DOI: 10.1002/pros.20134. View